Susquehanna International Group
GALT icon

Susquehanna International Group’s Galectin Therapeutics GALT Stock Holding History

Susquehanna International Group’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$123K Sell
44,200
-34,900
-44% -$106K ﹤0.01% 12198
2025
Q4 		$329K Buy
79,100
+10,100
+15% +$53.2K ﹤0.01% 9737
2025
Q3 		$293K Buy
69,000
+20,500
+42% +$77.1K ﹤0.01% 10164
2025
Q2 		$102K Sell
48,500
-13,500
-22% -$20.2K ﹤0.01% 11786
2025
Q1 		$75.6K Sell
62,000
-388,200
-86% -$545K ﹤0.01% 11699
2024
Q4 		$581K Buy
450,200
+434,500
+2,768% +$1.04M ﹤0.01% 8300
2024
Q3 		$43.2K Buy
+15,700
New +$38.6K ﹤0.01% 11436
2023
Q1 		– Sell
-23,800
Closed -$26.9K – 12882
2022
Q4 		$26.9K Sell
23,800
-49,900
-68% -$66.5K ﹤0.01% 11657
2022
Q3 		$120K Buy
73,700
+30,400
+70% +$56.8K ﹤0.01% 11518
2022
Q2 		$57K Sell
43,300
-61,800
-59% -$88.8K ﹤0.01% 11894
2022
Q1 		$169K Sell
105,100
-26,700
-20% -$51.7K ﹤0.01% 11441
2021
Q4 		$273K Sell
131,800
-111,800
-46% -$319K ﹤0.01% 10704
2021
Q3 		$945K Buy
243,600
+74,500
+44% +$253K ﹤0.01% 7703
2021
Q2 		$541K Buy
169,100
+90,600
+115% +$322K ﹤0.01% 9391
2021
Q1 		$170K Sell
78,500
-42,700
-35% -$95.7K ﹤0.01% 11554
2020
Q4 		$271K Buy
121,200
+52,600
+77% +$138K ﹤0.01% 9471
2020
Q3 		$183K Buy
68,600
+10,000
+17% +$28K ﹤0.01% 9527
2020
Q2 		$179K Sell
58,600
-19,800
-25% -$49.8K ﹤0.01% 9130
2020
Q1 		$154K Sell
78,400
-58,300
-43% -$142K ﹤0.01% 8964
2019
Q4 		$391K Buy
136,700
+3,700
+3% +$12.9K ﹤0.01% 7472
2019
Q3 		$488K Sell
133,000
-108,400
-45% -$392K ﹤0.01% 7354
2019
Q2 		$1M Sell
241,400
-57,100
-19% -$247K ﹤0.01% 5657
2019
Q1 		$1.52M Buy
298,500
+139,000
+87% +$667K ﹤0.01% 4212
2018
Q4 		$547K Sell
159,500
-79,700
-33% -$381K ﹤0.01% 5860
2018
Q3 		$1.44M Sell
239,200
-32,600
-12% -$179K ﹤0.01% 4558
2018
Q2 		$1.73M Buy
271,800
+172,100
+173% +$838K ﹤0.01% 4263
2018
Q1 		$473K Buy
99,700
+66,700
+202% +$311K ﹤0.01% 6748
2017
Q4 		$110K Sell
33,000
-89,200
-73% -$225K ﹤0.01% 8649
2017
Q3 		$259K Buy
122,200
+21,400
+21% +$42.4K ﹤0.01% 7627
2017
Q2 		$248K Buy
100,800
+81,400
+420% +$217K ﹤0.01% 7924
2017
Q1 		$45K Buy
+19,400
New +$29.2K ﹤0.01% 8621
2016
Q4 		– Sell
-11,100
Closed -$13K – 9757
2016
Q3 		$13K Sell
11,100
-400
-3% -$711 ﹤0.01% 8276
2016
Q2 		$17K Sell
11,500
-12,200
-51% -$17.9K ﹤0.01% 8389
2016
Q1 		$34K Sell
23,700
-21,000
-47% -$28.2K ﹤0.01% 8737
2015
Q4 		$73K Buy
44,700
+11,500
+35% +$26.3K ﹤0.01% 8995
2015
Q3 		$78K Sell
33,200
-41,000
-55% -$96.7K ﹤0.01% 9241
2015
Q2 		$203K Buy
74,200
+26,000
+54% +$78.4K ﹤0.01% 9264
2015
Q1 		$161K Sell
48,200
-108,600
-69% -$388K ﹤0.01% 8773
2014
Q4 		$544K Sell
156,800
-49,600
-24% -$219K ﹤0.01% 7051
2014
Q3 		$1.04M Buy
206,400
+4,200
+2% +$32.7K ﹤0.01% 5844
2014
Q2 		$2.79M Sell
202,200
-249,900
-55% -$3.11M ﹤0.01% 4025
2014
Q1 		$6.92M Buy
452,100
+383,300
+557% +$5.46M ﹤0.01% 2458
2013
Q4 		$556K Buy
68,800
+48,300
+236% +$446K ﹤0.01% 6520
2013
Q3 		$204K Buy
+20,500
New +$138K ﹤0.01% 7746

Other funds holding GALT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Susquehanna International Group's GALT Position: Q1 2026 in Review

Susquehanna International Group increased its Galectin Therapeutics (GALT) stake by 94% in Q1 2026, buying an estimated $818K and bringing the position to 555,702 shares worth $1.55M. The position accounts for ﹤0.01% of the portfolio, ranked #6791.

Susquehanna International Group first reported a position in GALT in Q4 2013 and has held it in 45 quarters since. The position peaked at $4.03M in Q1 2014. 98 funds tracked by Wall St. Rank hold GALT as of Q1 2026.

  • Susquehanna International Group held 555,702 shares of Galectin Therapeutics worth $1.55M as of Q1 2026.
  • Susquehanna International Group bought 268,783 Galectin Therapeutics shares in Q1 2026, an estimated $818K.
  • Galectin Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #6791 holding.
  • Susquehanna International Group first reported a position in Galectin Therapeutics in Q4 2013 and has held it in 45 quarters since.
  • Susquehanna International Group's Galectin Therapeutics position peaked at $4.03M in Q1 2014.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.